Supreme Court’s Mifepristone Ruling Leaves Coverage Quandary

Employers, health plans, and medical providers still face uncertainty over compliance and coverage of abortion drugs even after the US Supreme Court’s recent dismissal of a lawsuit challenging mifepristone’s approval temporarily resolved questions around patient access.

The high court’s ruling is only the latest iteration of a decades-long fight over abortion access—a fight that is still ongoing. Wide-ranging state laws and the potential for another challenge to the drug’s approval continue to pose a confusing web of regulations for clinicians and companies, attorneys say.

“I think most health care providers and industry members will likely yield to the state law ...